Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 2 ANVS Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects
May 2 ANVS Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
May 2 AMLX Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
May 2 AVXL Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
May 2 ANVS Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 1 AGEN Agenus regains compliance with Nasdaq minimum bid price requirement
May 1 AGEN Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
Apr 30 AGEN Time Is Running Out For Agenus To Raise Cash
Apr 30 AMLX Trials to watch: Four ALS drugs to keep an eye on
Apr 30 ATHE Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Apr 30 ANVS Annovis Bio: Searching For Efficacy In Alzheimer's Disease
Apr 29 ACAD Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
Apr 29 ANVS Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Apr 29 ANVS Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study
Apr 29 ANVS Annovis Bio tumbles 53% on data for Alzheimer's candidate buntanetap
Apr 29 ANVS UPDATE 2-Annovis tumbles as Alzheimer's treatment misses in mid-stage study
Apr 29 ANVS Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Apr 29 ATHE Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Apr 28 ACAD ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago
Apr 28 AGEN Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags